View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Lindsay Whipp
  • Lindsay Whipp

PSA Healthcare Technology: JMDC (4483 JT) Shares Turning a Corner?

JMDC's share price has started to turn around since the beginning of August. In this report, we explain why this is deserved.

Lindsay Whipp
  • Lindsay Whipp

PSA Small- and Mid-Cap IT Services: Game of Snakes and Ladders

Analyst Lindsay Whipp considers the small- and mid-cap IT service companies, weighing their generally poor and, arguably, erratic share price performance against their business prospects and valuations, and identifying opportunities.

Lindsay Whipp
  • Lindsay Whipp

PSA MedTech / Software: JMDC (4483 JT) Initiation – a Long-term Winner...

JMDC is battling to be Japan's number one healthcare big data company. In this report we examine the company's prospects in becoming so, and whether it's the sector's next M3?

JMDC sees a downgrade to Slightly Negative on account of less fundamen...

The independent financial analyst theScreener just lowered the general evaluation of JMDC (JP), active in the Business Support Services industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 25, 2022, the closing price was JPY 5,44...

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch